Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. boosted its position in Amgen Inc. (NASDAQ:AMGN) by 20.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 12,600 shares of the medical research company’s stock after purchasing an additional 2,100 shares during the period. Amgen comprises 1.1% of Hussman Strategic Advisors Inc.’s holdings, making the stock its 6th largest position. Hussman Strategic Advisors Inc.’s holdings in Amgen were worth $3,937,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the company. Kinsale Capital Group Inc. lifted its position in Amgen by 33.0% during the fourth quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock worth $3,269,000 after acquiring an additional 2,814 shares during the last quarter. Valley Brook Capital Group Inc. lifted its position in Amgen by 7.0% during the fourth quarter. Valley Brook Capital Group Inc. now owns 4,730 shares of the medical research company’s stock worth $1,362,000 after acquiring an additional 310 shares during the last quarter. Evergreen Wealth Management LLC raised its position in shares of Amgen by 1.7% in the fourth quarter. Evergreen Wealth Management LLC now owns 4,892 shares of the medical research company’s stock valued at $1,409,000 after buying an additional 84 shares in the last quarter. Axxcess Wealth Management LLC raised its position in shares of Amgen by 11.0% in the fourth quarter. Axxcess Wealth Management LLC now owns 15,362 shares of the medical research company’s stock valued at $4,425,000 after buying an additional 1,518 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its position in shares of Amgen by 2.7% in the fourth quarter. Cullen Frost Bankers Inc. now owns 89,834 shares of the medical research company’s stock valued at $25,874,000 after buying an additional 2,389 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on AMGN shares. Bank of America lifted their price target on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Oppenheimer reiterated an “outperform” rating and issued a $380.00 price target on shares of Amgen in a research report on Wednesday, August 7th. TD Cowen lifted their price target on shares of Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Morgan Stanley decreased their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price objective (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Eleven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $326.89.

Amgen Trading Up 0.9 %

Amgen stock traded up $2.82 during trading hours on Friday, reaching $333.83. The stock had a trading volume of 2,173,548 shares, compared to its average volume of 1,935,877. The company has a fifty day simple moving average of $324.99 and a 200-day simple moving average of $300.78. Amgen Inc. has a 52 week low of $248.38 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The stock has a market cap of $179.38 billion, a PE ratio of 47.69, a PEG ratio of 2.96 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The business had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company’s revenue was up 20.1% on a year-over-year basis. During the same period last year, the business earned $5.00 earnings per share. Analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.70%. Amgen’s dividend payout ratio is presently 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.